teaser
↓Article continues below this sponsored advert↓
Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.
↑Advertisement↑
Treatment with an angiotensin II receptor type I blocker (ARB) before and after electrical cardioversion does not reduce recurrence of atrial fibrillation (AF), results of a randomised, placebo-controlled trial indicate.
Patients with persistent AF are usually treated using a “rhythm-control” strategy with electrical cardioversion used to restore sinus rhythm, explained Dr Arnljot Tveit of Asker and B
